Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$68.86 - $83.34 $11.4 Million - $13.8 Million
-165,000 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$96.85 - $148.25 $122 Million - $186 Million
-1,257,932 Reduced 88.4%
165,000 $16.3 Million
Q3 2020

Nov 12, 2020

BUY
$122.47 - $213.56 $158,231 - $275,919
1,292 Added 0.09%
1,422,932 $202 Million
Q2 2020

Aug 13, 2020

BUY
$185.52 - $231.25 $2.8 Million - $3.49 Million
15,097 Added 1.07%
1,421,640 $280 Million
Q1 2020

May 13, 2020

SELL
$143.0 - $274.03 $18.6 Million - $35.7 Million
-130,219 Reduced 8.47%
1,406,543 $276 Million
Q4 2019

Feb 14, 2020

SELL
$146.12 - $215.82 $6.11 Million - $9.02 Million
-41,801 Reduced 2.65%
1,536,762 $318 Million
Q3 2019

Nov 14, 2019

SELL
$130.44 - $187.64 $14.4 Million - $20.7 Million
-110,285 Reduced 6.53%
1,578,563 $241 Million
Q2 2019

Aug 14, 2019

BUY
$111.45 - $128.93 $1.08 Million - $1.25 Million
9,730 Added 0.58%
1,688,848 $218 Million
Q1 2019

May 10, 2019

BUY
$89.61 - $117.78 $26,883 - $35,334
300 Added 0.02%
1,679,118 $198 Million
Q4 2018

Feb 13, 2019

BUY
$87.81 - $110.65 $78,677 - $99,142
896 Added 0.05%
1,678,818 $154 Million
Q3 2018

Nov 13, 2018

BUY
$90.63 - $120.22 $22.9 Million - $30.4 Million
253,159 Added 17.77%
1,677,922 $189 Million
Q2 2018

Aug 10, 2018

BUY
$88.4 - $105.34 $10.7 Million - $12.8 Million
121,415 Added 9.32%
1,424,763 $131 Million
Q1 2018

May 09, 2018

SELL
$94.51 - $120.23 $4.46 Million - $5.67 Million
-47,186 Reduced 3.49%
1,303,348 $130 Million
Q4 2017

Feb 14, 2018

BUY
$84.48 - $104.02 $78,904 - $97,154
934 Added 0.07%
1,350,534 $0
Q3 2017

Nov 13, 2017

BUY
$73.17 - $103.47 $98.8 Million - $140 Million
1,349,600
1,349,600 $137 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.9B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.